Navigation Links
WaferGen Announces Organizational Changes to Enhance Commercialization of SmartChip System
Date:10/20/2011

FREMONT, Calif., Oct. 20, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today announced organizational changes to strengthen domain leadership and enhance commercialization expertise required to increase the adoption of its SmartChip System.  

As an initial step, the company has engaged Steve Lombardi, formerly President and a director of Helicos BioSciences Corporation, as a consultant to work with management and provide strategic guidance.  Mr. Lombardi has significant domain expertise from his 30 plus years in this field in roles with Helicos, Affymetrix and Applied Biosystems.

After successfully bringing the company to the point of initial commercialization, Alnoor Shivji will step aside as WaferGen's Chief Executive Officer and President effective immediately, and will continue to serve as WaferGen's Chairman of the Board.  Until a permanent replacement Chief Executive Officer is appointed, a new Office of the President has been formed to assume the primary executive officer functions, and will consist of Mona Chadha, Chief Operating Officer, Executive Vice President and Secretary, and Donald Huffman, Chief Financial Officer.

"These organizational changes will provide the leadership to guide WaferGen through the next phase of commercialization of the SmartChip System," said Joel Kanter, Chairman of WaferGen's Audit and Compensation Committees.

"We want to thank Alnoor for his immense contributions as Chief Executive Officer to the development of WaferGen's unique and significant technological achievements during the development stage of the company. His accomplishments as the Chief Executive Officer of a number of successful start-up technology companies enabled us to achieve engineering outcomes many thought impossible, and left us prepared to tackle the challenges of commercialization. Alnoor will continue to work with us as Chairman of the Board to achieve those objectives."

Ms. Chadha joined the company in 2006 as Vice President, Marketing and Business Development and was promoted to Chief Operating Officer and Executive Vice President in February 2010.  She has more than 20 years of domain expertise in life sciences with leading biotechnology companies.  Mr. Huffman has served as the company's Chief Financial Officer since September 2010.  Mr. Huffman brings more than 30 years of corporate development and senior financial management experience to WaferGen.   

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., an emerging genomic analysis company in the early stage of commercialization, offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform.  The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and Single Nucleotide Polymorphism (SNP) genotyping.  WaferGen also offers Quick-Turnaround SmartChip Custom (User-Defined) Panels to enable validation studies of specific genes of interest through customization of high-throughput, real-time PCR SmartChip assay panels—all on a quick-turnaround basis.

In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains certain "forward-looking statements".  Such statements include statements relating to management changes and WaferGen's transition to a permanent CEO, and other statements relating to future events are not historical facts, including statements which may be preceded by the words "will," "believes" or similar words.  Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.  More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2010 and the company's most recent Quarterly Report on Form 10-Q for the period ended June 30, 2011.  Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov.  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts:
WaferGen
510-651-4450

Don Huffman, CFO
don.huffman@wafergen.com

Media:  Joyce Strand
Joyce.strand@wafergen.com

Investors: Tim Ryan
tryan@shorehamgroupllc.com
212-242-7777


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
2. WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System
3. WaferGen Reports Second Quarter 2010 Financial Results
4. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
5. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
6. WaferGen to Present at OneMedForum San Francisco 2011
7. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
8. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
9. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
10. WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
11. WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel V2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... of providing a voice for people who have kidney disease. The theme “Describe ... to share their stories. Entrants needed to meet only one qualification— to ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... roster of exhibitors at the East-coast edition of MarTech: The Marketing Tech Conference ... will bring together more than 40 speakers — representing such thought-leading companies ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and Medicaid Services ... will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated ... 60-minute complimentary webinars on October 17, 2017 at 2 P.M. EST and ...
(Date:9/20/2017)... ... ... Trials I Face to Receive God’s Grace”: a mesmerizing take on one man’s ... one’s life through God. “The Trials I Face to Receive God’s Grace” is the ... a love for writing. Green feels that expressing his feelings through prayer will present ...
Breaking Medicine News(10 mins):